KalVista Pharmaceuticals (NASDAQ: KALV) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare KalVista Pharmaceuticals to related businesses based on the strength of its earnings, institutional ownership, dividends, profitability, risk, valuation and analyst recommendations.

Valuation & Earnings

This table compares KalVista Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
KalVista Pharmaceuticals $1.50 million -$18.60 million -3.04
KalVista Pharmaceuticals Competitors $564.12 million $96.17 million 61.61

KalVista Pharmaceuticals’ rivals have higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares KalVista Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
KalVista Pharmaceuticals -4,191.47% -60.42% -55.11%
KalVista Pharmaceuticals Competitors -13,603.82% -109.96% -27.55%

Institutional and Insider Ownership

76.1% of KalVista Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.5% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 49.1% of KalVista Pharmaceuticals shares are owned by insiders. Comparatively, 15.4% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for KalVista Pharmaceuticals and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KalVista Pharmaceuticals 0 0 1 0 3.00
KalVista Pharmaceuticals Competitors 137 801 1761 59 2.63

KalVista Pharmaceuticals currently has a consensus target price of $27.00, suggesting a potential upside of 176.92%. As a group, “Biopharmaceuticals” companies have a potential upside of 11.23%. Given KalVista Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe KalVista Pharmaceuticals is more favorable than its rivals.

Summary

KalVista Pharmaceuticals beats its rivals on 7 of the 11 factors compared.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.

Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.